Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $617.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: -22.52%
• EPS Growth: -37.00%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 144,677,780
• 10 Day Avg. Volume: 1,411,357
• 30 Day Avg. Volume: 1,538,557
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 10.36
• Enterprise Value/Ebitda: -2.29
• 1Y Price Target: $4.13
• Price Target Upside: 77.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 44 Neutral
• Price Target: $2.50 ▲(7.30% Upside)

Maravai Lifesciences Holdings faces significant financial and operational challenges, as reflected in its low financial performance score. The technical analysis shows mixed signals, and the valuation is unattractive due to negative earnings. While restructuring efforts and strategic initiatives offer some hope, the overall outlook remains pressured by declining revenues and profitability.

Positive Factors

Leadership and Experience

Raj Asarpota's extensive experience in leading global acquisitions and driving operational efficiencies is aligned with the company's focus on financial discipline.

Potential Acquisition

There is speculation about a potential acquisition of Maravai, which could lead to increased investor interest and potential premium offers.

Strategic Review

An active strategic review of future direction (and the assets involved) is ongoing with an update coming sooner rather than later.

Negative Factors

Financial Uncertainty

The company has not updated its full-year 2025 financial guidance, leaving investors uncertain about future financial performance.

Non-COVID Business Challenges

Maravai's non-COVID business has declined year-over-year for nine consecutive quarters, indicating persistent challenges in its key end-markets.

Revenue Headwinds

The company is facing a $66 million headwind in 2025 due to the impact of COVID revenues rolling off its P&L statement.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

How the Company Makes Money

Maravai Lifesciences Holdings makes money primarily through the sale of its life science products and services. The company generates revenue by providing high-quality reagents and services that are critical in the development and manufacturing processes of biopharmaceuticals and diagnostics. Key revenue streams include nucleic acid products, which are essential for mRNA-based therapies and vaccines, biologics safety testing for ensuring the safety and efficacy of drugs, and protein detection products used in research and development. Significant partnerships with biotech firms and research institutions also contribute to its earnings by expanding its market reach and customer base.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences Holdings is facing significant financial challenges, with declining revenue and profitability impacting its income statement. The balance sheet shows reduced leverage but negative returns on equity. Cash flow improvements are noted, but overall cash generation remains a concern. The company needs to address operational inefficiencies and improve revenue growth to enhance financial stability.

Income Statement

Maravai Lifesciences Holdings has experienced a significant decline in revenue and profitability over the TTM period. The gross profit margin has decreased from previous years, and the net profit margin is negative, indicating losses. Revenue growth has been negative, reflecting a challenging market environment. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio in the TTM period, which is a positive sign of reduced leverage. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholder investments. The equity ratio is stable, but the overall financial health is impacted by declining profitability.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow growth, although it remains negative. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	215.85M	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	62.83M	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-284.12M	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-194.72M	-144.85M	-119.03M	220.21M	182.04M	76.89M
Balance Sheet
Total Assets	896.97M	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	269.91M	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	371.08M	376.69M	610.97M	585.26M	575.22M	590.78M
Total Liabilities	428.98M	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	265.86M	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-44.21M	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	-21.16M	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-40.26M	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-240.57M	-235.71M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.45, and below the 200-day MA of 3.36, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.76 is Neutral, neither overbought nor oversold. The STOCH value of 14.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	67 Neutral	$928.61M	―	-3.40%	―	22.68%	42.45%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
IMNM	48 Neutral	$884.38M	―	-81.20%	―	16.74%	59.89%
BCAX	48 Neutral	$656.94M	―	-32.71%	―	―	―
LENZ	46 Neutral	$1.10B	―	-26.25%	―	―	79.90%
MRVI	44 Neutral	$617.98M	―	-55.41%	―	-22.52%	-37.00%
COGT	37 Underperform	$1.71B	―	-107.55%	―	―	2.25%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Announces Major Organizational Restructuring

On August 11, 2025, Maravai LifeSciences announced an organizational restructuring to reduce operating costs, including a workforce reduction affecting approximately 25% of its employees. This strategic initiative, committed to on August 8, 2025, is expected to incur costs between $8.0 million and $9.0 million, primarily for employee severance and benefits. Additionally, the company reported a significant decrease in revenue for the second quarter of 2025, with a 31.7% drop compared to the previous year, largely due to reduced CleanCap orders. Despite this, Maravai is implementing cost-saving measures expected to save over $50 million annually, aiming to realign its cost structure and return to profitability.

Maravai Lifesciences Appoints New CFO Rajesh Asarpota

On June 22, 2025, Maravai LifeSciences announced the appointment of Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde. Mr. Asarpota, with extensive experience in finance and strategic growth in the life sciences and medical device sectors, will lead Maravai’s financial and strategic initiatives, supporting its focus on nucleic acid technologies and bioprocess impurity analytics. This transition aims to strengthen Maravai’s leadership team and drive long-term value creation for stakeholders.

Maravai Lifesciences Appoints Bernd Brust as New CEO

On June 8, 2025, Maravai LifeSciences Holdings appointed Bernd Brust as the new CEO and member of the Board, succeeding William E. Martin, III. This leadership transition aims to enhance innovation and financial performance, with Brust bringing over 30 years of experience in the life sciences industry. The company is poised for long-term success with a strong financial foundation and a commitment to expanding its market leadership in mRNA and bioprocess impurity detection. Maravai plans to continue delivering innovative solutions to researchers and biotech innovators globally.

Maravai Lifesciences Holds Annual Shareholders Meeting

On May 22, 2025, Maravai LifeSciences Holdings, Inc. conducted its Annual Meeting of Shareholders. During the meeting, shareholders elected directors for three-year terms, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding advisory basis.